- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Anonymous complaint alleged misleading trial claims and a “switch programme” for Adcal-D3 Caplet. Panel found no breach for promo materials or therapy…
Pharmacosmos alleged Vifor reps misled HCPs that Monofer total dose infusion had a 1,000mg max. Panel found evidence insufficient on balance of…
Anonymous complaint alleged two Allergan employees were removed from a Merz symposium for photographing/recording despite warnings. Panel found insufficient evidence of poor…
A GP alleged Trajenta “with a difference” claims were misleading vs other DPP-4 inhibitors (dose adjustment, renal monitoring, food). Panel and Appeal…
A GP said he was misled into attending what he thought was EvoInserter training for Mirena. PMCPA found the ‘Mirena training workshop’…
Anonymous NHS HCPs complained about excessive hospitality at a 5-star Belfast urology meeting with golf and a gala dinner. Janssen was found…
Anonymous complaint alleged Chugai staff bought rounds of drinks for health professionals in a hotel bar after a conference dinner. Chugai denied…
A GP complained that Hidrasec ads were visible on Facebook. The Panel ruled this effectively promoted a prescription-only medicine to the public…
A pharmacist alleged Leo’s pre-printed ‘Dear Dr’ forms for Picato were used to bypass local formulary status. PMCPA found the material didn’t…
Shire self-referred use of a Lancet reprint containing an incorrect bar chart about competitor Fabrazyme. Although the correction was included at the…
Astellas admitted an error in a BMJ-distributed “consensus statement” where the sponsorship declaration understated its role. The Panel found disguised promotion, misleading…
Bausch & Lomb was ruled in breach after “new” claims for Emerade remained on an HCP website page despite an undertaking in…
Complaint alleged off-label discussion and research grant promotion at a Boehringer Ingelheim ESC 2015 symposium. Panel found no evidence of off-label promotion…
PMCPA found Bayer’s DMO e-detailer/briefing implied Eylea superiority vs Lucentis using unlicensed Lucentis dosing without clear status. Breaches of Clauses 7.2, 7.3,…
Anonymous GP challenged Triumeq BMJ ad claims (“inner strength” and superiority vs Atripla in treatment-naïve patients). Panel found a narrow breach of…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.